ID: ALA250871

Max Phase: Preclinical

Molecular Formula: C14H15N3O2

Molecular Weight: 257.29

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1NCCc2c1cc(-c1ccncc1)n2CCO

Standard InChI:  InChI=1S/C14H15N3O2/c18-8-7-17-12-3-6-16-14(19)11(12)9-13(17)10-1-4-15-5-2-10/h1-2,4-5,9,18H,3,6-8H2,(H,16,19)

Standard InChI Key:  LWFINZKGSCYRMI-UHFFFAOYSA-N

Associated Targets(Human)

CDC7 Tchem Cell division cycle 7-related protein kinase (1385 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PKN2 Tchem Protein kinase N2 (1991 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PKN1 Tchem Protein kinase N1 (787 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 257.29Molecular Weight (Monoisotopic): 257.1164AlogP: 0.83#Rotatable Bonds: 3
Polar Surface Area: 67.15Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 5.05CX LogP: -0.26CX LogD: -0.26
Aromatic Rings: 2Heavy Atoms: 19QED Weighted: 0.86Np Likeness Score: -0.36

References

1. Vanotti E, Amici R, Bargiotti A, Berthelsen J, Bosotti R, Ciavolella A, Cirla A, Cristiani C, D'Alessio R, Forte B, Isacchi A, Martina K, Menichincheri M, Molinari A, Montagnoli A, Orsini P, Pillan A, Roletto F, Scolaro A, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C..  (2008)  Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.,  51  (3): [PMID:18201066] [10.1021/jm700956r]
2. Scott F, Fala AM, Takarada JE, Ficu MP, Pennicott LE, Reuillon TD, Couñago RM, Massirer KB, Elkins JM, Ward SE..  (2022)  Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery.,  60  [PMID:35104640] [10.1016/j.bmcl.2022.128588]

Source